Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16616069 | 0.92 | MEN1 (0.40) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL27087739 | 0.76 | LMNA (0.44) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL17094558 | 0.74 | KDM6B (0.44) | HTTL3MBTL1LMNAALDH1A1 | |
| SCHEMBL2574651 | 0.73 | MEN1 (0.33) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL1284719 | 0.71 | MEN1 (0.39) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL607874 | 0.70 | SMN1; SMN2 (0.40) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL22656967 | 0.69 | ALDH1A1 (0.36) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL3539586 | 0.68 | L3MBTL1 (0.35) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL8773482 | 0.67 | MEN1 (0.69) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL25244288 | 0.67 | MEN1 (0.33) | MEN1KMT2AHTTL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533957-B2 | Tetrazines and method of synthezising the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150099277-A1 | NOVEL TETRAZINES AND METHOD OF SYNTHEZISING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099277-A1 | NOVEL TETRAZINES AND METHOD OF SYNTHEZISING THE SAME | NBAS, NAA15, TALDO1 | MEN1 1693/4885KMT2A 1569/4885HTT 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.